NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 89 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 2.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $20,000 | -79.6% | 771 | -79.0% | 0.00% | – |
Q4 2020 | $98,000 | +444.4% | 3,671 | +232.5% | 0.00% | – |
Q3 2020 | $18,000 | -50.0% | 1,104 | -41.3% | 0.00% | – |
Q2 2020 | $36,000 | +260.0% | 1,881 | +130.5% | 0.00% | – |
Q1 2020 | $10,000 | -82.5% | 816 | -73.4% | 0.00% | – |
Q4 2019 | $57,000 | +612.5% | 3,072 | +412.9% | 0.00% | – |
Q3 2019 | $8,000 | 0.0% | 599 | +8.7% | 0.00% | – |
Q2 2019 | $8,000 | – | 551 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |